Sentiment Trading

RaySearch Laboratories AB reported a record-breaking first quarter in 2025, with significant increases in order intake, net sales, and operating profit, driving a 20% surge in its stock price.

RaySearch Laboratories AB reported a record-breaking first quarter in 2025, with sales and profits exceeding expectations, driven by strong demand for its cancer treatment solutions.

RaySearch Laboratories AB reported strong first quarter financials, with significant growth in order intake, net sales, and operating profit, driven by increased adoption of its radiation therapy solutions.

RaySearch Laboratories AB reported a strong start to 2025 with a 72% increase in order intake and 29% rise in net sales, driven by the success of its flagship product RayStation and strategic developments in oncology information systems.